Word

VECTURA

Status

Dead

Status Code

709

Status Date

Friday, June 7, 2024

Serial Number

79202821

Registration Number

5337619

Registration Date

Tuesday, November 21, 2017

Mark Type

3

Filing Date

Friday, November 25, 2016

Published for Opposition

Tuesday, September 5, 2017

Cancellation Date

Friday, June 7, 2024

Trademark Owner History

Vectura Limited - Original Registrant

Classifications

5 Pharmaceutical and biological preparations for medical purpose, namely for the treatment of diseases or conditions of the respiratory system; pharmaceutical and biological preparations for medical purposes, namely the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynaecological conditions; pharmaceutical and biological preparations for medical purposes, namely for the alleviation or prevention of pain or inflammation; pharmaceutical and biological preparations for medical purposes, namely, powders for asthma inhalers; pharmaceutical and biological preparations for medical purposes, namely, powders for transdermal injection for the alleviation or prevention of pain, for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purposes, namely for oral ingestion for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genitourinary system, infections, skin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purposes, namely for topical administration for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purpose, namely, medicaments for inhalation therapy; pharmaceutical and biological preparations for medical purposes, namely, pulmonary delivery compositions for use in facilitating the inhalation of pharmaceuticals, namely, drug delivery agents consisting of compounds that facilitate delivery by inhalation of a wide range of pharmaceuticals; pharmaceutical and biological preparations for medical purpose, namely medicaments for the treatment of erectile dysfunction, medicaments for the treatment of chronic obstructive pulmonary disease, medicaments for the treatment of premature ejaculation, medicaments for the treatment of cystic fibrosis, medicaments for the treatment of female sexual dysfunction, medicaments for the treatment of migraines, and medicaments for the treatment of asthma

10 Drug delivery devices, namely, drug delivery systems; inhalers for medical use; metered dose inhalers for medical use; active dry powder inhalers for medical use; passive dry powder inhalers for medical use; nebulisers for respiration therapy; respirators for artificial respiration; parts and fittings for all the aforesaid goods

42 Scientific research, development, design, analysis, testing and investigation relating to medical preparations and drug delivery devices; medical research; research relating to drug delivery devices; research relating to drug formulation; pharmaceutical development; preparation and formulation of pharmaceuticals; device and product testing namely device and product testing of drug delivery devices and medical preparations

The mark consists of a letter "V" made up of 6 oblique lines and a small triangle. The upper right corner of the "V" is blue and the lower left corner is blue. The mark also features the word "VECTURA" in blue. The background of the mark is white.
Green upper right corner of "V" device; blue lower left corner of "V" device; blue wording.
The color(s) blue, green, and white is/are claimed as a feature of the mark.

Trademark Events

Mar 9, 2017

Sn Assigned For Sect 66a Appl From Ib

Mar 10, 2017

New Application Office Supplied Data Entered

Mar 11, 2017

Assigned To Examiner

Mar 14, 2017

Application Filing Receipt Mailed

Mar 15, 2017

Non-Final Action Written

Mar 16, 2017

Non-Final Action (Ib Refusal) Prepared For Review

Mar 16, 2017

Refusal Processed By Mpu

Mar 16, 2017

Non-Final Action Mailed - Refusal Sent To Ib

Apr 2, 2017

Refusal Processed By Ib

Jul 20, 2017

Teas Response To Office Action Received

Jul 23, 2017

Approved For Pub - Principal Register

Jul 20, 2017

Correspondence Received In Law Office

Jul 21, 2017

Teas/Email Correspondence Entered

Aug 16, 2017

Notification Of Notice Of Publication E-Mailed

Sep 5, 2017

Published For Opposition

Sep 5, 2017

Official Gazette Publication Confirmation E-Mailed

Nov 21, 2017

Registered-Principal Register

Feb 21, 2018

Final Disposition Notice Created, To Be Sent To Ib

Mar 2, 2018

Final Disposition Processed

Mar 3, 2018

Final Disposition Notice Sent To Ib

Nov 21, 2022

Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed

Dec 22, 2023

New Representative At Ib Received

Apr 27, 2018

Final Decision Transaction Processed By Ib

Oct 8, 2022

New Representative At Ib Received

Jun 7, 2024

Cancelled Section 71